Catherine Aubry

Title: **Catherine Aubry: A Pioneer in Mucoadhesive Therapeutics**

Introduction

Catherine Aubry, an innovative inventor based in Lure, France, has made significant contributions to the field of therapeutic and hygienic compositions. With a focus on formulations intended for administration via the buccal or nasal mucous membranes, her work is crucial in both human and veterinary medicine.

Latest Patents

Aubry holds a noteworthy patent for a "Solid mucoadhesive therapeutic or hygienic composition." This patented composition includes a mixture of ingredients designed for efficacy in applications to mucous membranes. The formulation consists of 15 to 25% by weight of a cellulosic ether that gels in the presence of water, 10 to 15% by weight of a homopolymer or copolymer of acrylic acid (or a physiologically acceptable salt), 30 to 45% by weight of gelatin, along with one or more therapeutic or hygienic active constituents. The cellulosic ether is preferably a C1-C4 alkyl ether of cellulose or its hydroxyalkyl variants.

Career Highlights

Aubry is currently affiliated with Vetoquinol S.A., a company renowned for its commitment to the veterinary sector. Her career has been marked by innovative strides in mucoadhesive therapies, providing crucial advancements in the administration methods of therapeutic agents.

Collaborations

Throughout her career, Catherine Aubry has worked alongside esteemed colleagues such as Yves R. Jacques and Claude Gaillard. These collaborations have bolstered her research efforts and expanded the impact of her innovations in the field.

Conclusion

Catherine Aubry stands as a prominent figure in the realm of mucoadhesive therapeutics, exemplifying innovation and collaboration. Her patented work continues to pave the way for advancements in therapeutic applications, enhancing patient care in both human and veterinary medicine.